Innovative Drug Development Solutions for Neurodegenerative Diseases
SeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology
A SeNostic Company Presentation
SeNostic aims to enhance patient care and facilitate drug development for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, addressing unmet needs with innovative technology and strategic collaborations.
The core of SeNostic’s innovation lies in its exploitation of misfolded proteins, such as α-synuclein, tau, and amyloid-β, which are biomarkers for neurodegenerative diseases. These proteins exhibit prion-like behavior, transferring their misfolded structures to normal proteins, causing the formation and accumulation of insoluble aggregates in the brain. This process disrupts normal brain functionality and leads to disease progression.
SeNostic’s patented diagnostic approach uses this pathological mechanism to detect these misfolded proteins. By inducing and amplifying protein aggregation, the company mimics the disease mechanism to provide a direct, sensitive, and reliable readout. The resulting fluorescence aggregation kinetics offer critical insights into the disease type, stage, and potential progression.
Central to SeNostic’s technology is the SeedCycler, a patented analytical device designed to measure fluorescence aggregation kinetics. This innovative technology ensures exceptional sensitivity, allowing for the early detection of biomarkers in bodily fluids such as cerebrospinal fluid (CSF) and blood. The SeedCycler also facilitates high-throughput screenings for drug discovery, enabling researchers to analyse mutations and strains of biomarkers effectively.
SeNostic’s solutions have far-reaching applications in both clinical and pharmaceutical contexts. For early detection, the technology enables highly sensitive biomarker identification in body fluids, which can significantly improve diagnostic precision and patient outcomes. In drug discovery, the company’s approach helps identify interfering substances and drug efficacy at a molecular level. Additionally, the technology is valuable in clinical trials, where it aids in characterising patients and understanding biomarker strain relationships to evaluate drug effectiveness.
For detailed information, please download the free .PDF presentation by completing the form.
DOWNLOAD THE FULL .PDF SOLUTIONS OVERVIEW
